|
|
|
Andrew Crockett, MBA – Chief Executive Officer
|
|
|
| Andrew is a co-founder of KalVista Pharmaceuticals and its CEO. He is also CEO of Vantia Therapeutics, which he joined in 2009 from the US specialty pharma company ZARS Pharma. During his career he has identified, negotiated and executed strategic corporate transactions on a global basis, including merger and acquisitions, national and international product licences, IP and technology licences, and R&D alliances.
Andrew has studied at Harvard Business School and holds an MBA from The Wharton School, University of Pennsylvania, with a major in Finance.
|
|
 |
|
Robert Haigh, PhD – Chief Operating Officer
|
|
|
| Robert holds a Masters in Biochemistry and a PhD in Medicine, both from Manchester University. Following a successful Research Fellowship at Oxford University, he began his pharmaceutical career in drug discovery and has held positions of increasing responsibility in R&D during a 20-year career with Boehringer Ingelheim, Ferring Pharmaceuticals and Vantia Therapeutics.
As Managing Director and VP Research at Ferring, Robert led the spin-out of the UK site in 2008 to become a Founder of Vantia Ltd. Robert was instrumental to the acquisition of KalVista’s discovery assets from Vantia, where he was previously CSO and had delivered successful discovery programmes and novel targets.
During his career, he has lived and worked in the UK and Germany and has held board level positions in Europe and the USA.
Robert is a co-founder of KalVista Pharmaceuticals.
|
|
 |
|
Stephen Donnelly – Chief Financial Officer
|
|
|
| Stephen has more than ten years’ experience working with healthcare companies. He holds professional accounting and company secretarial qualifications and previous positions in the industry include Chief Accountant/Company Secretary for Anagen PLC, a diagnostic company quoted on the LSE, and CFO/Company Secretary of Alfa Biotech (UK) Limited, a UK subsidiary of an Italian pharmaceutical company.
Stephen has also held senior management positions with other venture capital backed healthcare companies including Novarticulate Holdings Ltd and Rodaris Pharmaceuticals Ltd, and is currently CFO of Vantia Therapeutics. In addition to these roles in the healthcare industry he also held the position of Director of Finance and Administration for the London Office of The Nasdaq Stock Market Inc.
|
|
 |
|
Chris Yea - Head of Development
|
|
|
|
Chris holds a BSc and PhD in Biochemistry from the University of Bristol, UK. Following post-doctoral work in the area of immunology he spent several years at Hoechst Marion Roussel before joining Ferring Pharmaceuticals. In 2008 Chris co-founded Vantia Therapeutics where he currently holds the position of Chief Operating Officer.
Chris joined KalVista Pharmaceuticals as Head of Development in 2012.
|
|
 |
|
Robert Tansley - Medical Director
|
|
|
|
Robert has 16 years industry in a range of pharmaceutical, biotechnology and regulatory organisations including Sanofi, the MHRA, Arakis and Roche. He has extensive global development, regulatory, and licensing experience including successful global NDAs and launches. During his time in the Licensing Division of the MHRA, Robert gained strong regulatory exposure to add to his industry experience. Commercially, Robert has worked on the launch of a wide range of products both in the UK and globally and has been involved in the in-licensing and out-licensing of projects both in the large pharma and biotech setting. His commercial experience has been supplemented with an MBA from London Business School (passed with distinction). Robert qualified in medicine from University College London, subsequently obtaining membership of the Royal College of Obstetricians & Gynaecologists and the Faculty of Pharmaceutical Medicine (where he is currently on the Examinations Committee) and has an M.Phil in Biostatistics from the University of Cambridge.
Robert joined KalVista Pharmaceuticals as Medical Director in 2012.
|
|
 |
|
SENIOR ADVISORS
|
|
|
|
Gary Cook, Ph.D – CMC/Pharmaceutical Development
|
|
|
| Dr. Cook has focused on developing injectable extended release and novel ophthalmic formulations for the past decade. Previously, he was vice president of pharmaceutical development at Jerini Ophthalmic, Inc. At Jerini, he led CMC and non-clinical development programs for immediate and extended release injectable ophthalmic formulations for two drug substances, before the company was acquired by Shire plc in 2008. Prior to Jerini, Dr. Cook was senior director of chemistry and drug delivery at Eyegate Pharma, where he identified and initiated development of a dexamethasone formulation currently in Phase III clinical trials. He also worked at Eyetech Pharmaceuticals, where he led the successful effort to identify and demonstrate the utility of a multi-month extended release formulation of pegaptanib sodium.
Preceding the focus in ophthalmology, Dr. Cook worked in various scientific roles at NeXstar Pharmaceuticals, Gilead Sciences and PR Pharmaceuticals using chemistry, formulation and drug delivery technologies to increase the utility of biotech derived therapeutic agents. He is co-author on patents for preparation of macromolecular conjugates, polymer-based extended release formulations, and iontophoretic ocular drug delivery. He currently runs an independent pharmaceutical drug development consulting business. Dr. Cook received his Ph.D. in physical organic chemistry from Colorado State University.
|
|
|
|
Marlene Modi, PhD – Toxicology
|
|
|
| Marlene is an experienced ophthalmic toxicologist and clinical pharmacologistwith more than 20 years of experience in the pharmaceutical industry. Most recently, she served as Vice President, Preclinical Development at Optherion Inc. and before that she was Senior Director of Clinical Pharmacology at Eyetech Pharmaceuticals, Inc. For the previous 15 years, Marlene worked at Hoffmann-La Roche in key management positions, including Site Head and Director of Clinical Pharmacology. She has extensive expertise in the areas of preclinical and clinical development of large molecules (e.g. proteins, monoclonal antibodies, aptamers and pegylated compounds). Her work has included the therapeutic areas of ophthalmology, virology, infectious disease, neurology, oncology, diabetes and asthma. She received a BS in Pharmacy from the University of Houston and a PhD in Pharmaceutics from the State University of New York at Buffalo. |
|
|
|
Rachel Morten – Regulatory Affairs
|
|
|
| Rachel has more than 24 years’ experience in global regulatory affairs and product development in the pharmaceutical and animal health industries. She is currently Head of Regulatory Affairs at Vantia Therapetics. Prior to this, Rachel was an independent regulatory affairs consultant, and she has also served as Senior Director, Group Head Regulatory Affairs for the international CRO Averion International Ltd (previously Hesperion). Rachel founded ChapelPharma, a regulatory consultancy that was acquired by Hesperion in 2004. |
|
|
|
